Michael Burkes Brophy Sells 1,886 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 1,886 shares of Natera stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $176.60, for a total value of $333,067.60. Following the completion of the sale, the chief financial officer now directly owns 101,811 shares in the company, valued at $17,979,822.60. This represents a 1.82 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The stock was sold at an average price of $165.87, for a total transaction of $719,046.45.
• On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The stock was sold at an average price of $161.87, for a total transaction of $233,416.54.
• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The shares were sold at an average price of $171.98, for a total transaction of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $4,277,837.07.

Natera Price Performance

Shares of NTRA traded down $2.32 during trading hours on Tuesday, hitting $174.24. 1,123,762 shares of the company were exchanged, compared to its average volume of 1,398,269. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a fifty-two week low of $66.68 and a fifty-two week high of $183.00. The company has a market cap of $23.00 billion, a price-to-earnings ratio of -99.00 and a beta of 1.66. The firm's fifty day moving average is $167.14 and its 200 day moving average is $139.03.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business's revenue for the quarter was up 63.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.95) earnings per share. On average, equities analysts anticipate that Natera, Inc. will post -1.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its stake in shares of Natera by 205.4% in the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company's stock valued at $355,493,000 after purchasing an additional 1,883,481 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Natera by 3.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company's stock worth $315,194,000 after buying an additional 85,236 shares during the last quarter. Geode Capital Management LLC boosted its stake in Natera by 7.4% in the third quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company's stock valued at $265,747,000 after buying an additional 143,825 shares in the last quarter. Maverick Capital Ltd. grew its position in Natera by 25.2% in the third quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company's stock valued at $170,119,000 after acquiring an additional 269,706 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Natera by 25.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,229,558 shares of the medical research company's stock worth $156,092,000 after acquiring an additional 246,246 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. TD Cowen upped their target price on Natera from $155.00 to $175.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Sanford C. Bernstein upped their price objective on Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a research note on Friday, January 10th. Leerink Partners raised their target price on shares of Natera from $140.00 to $150.00 and gave the company an "outperform" rating in a research note on Thursday, October 17th. Canaccord Genuity Group upped their price target on shares of Natera from $165.00 to $180.00 and gave the stock a "buy" rating in a research report on Friday, January 3rd. Finally, Robert W. Baird lifted their price objective on shares of Natera from $120.00 to $160.00 and gave the company an "outperform" rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company's stock. Based on data from MarketBeat, Natera currently has a consensus rating of "Moderate Buy" and a consensus target price of $165.88.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.